Commentary

Pregnancy in the cancer survivor


 

References

What to consider when counseling cancer survivors about pregnancy

• The recommended disease-free interval prior to pregnancy may vary by cancer type, and is largely driven by disease surveillance needs and recurrence intervals.

• Prior cancer, associated operations, and chemotherapies do not typically confer additional risks in pregnancy. Exceptions include melanoma and blood cell cancers, which may metastasize to the placenta and fetus, even following periods of remission.

• Radiation therapy to the abdomen and pelvis may induce changes that predispose to growth restriction, preterm birth, and stillbirth. Enhanced surveillance may be reasonable in these cases.

• Preconception or early pregnancy assessment for end organ dysfunction is recommended for women who have received certain therapies: cardiac evaluation following chest radiation or anthracycline-based therapy; liver and kidney function for most chemotherapies.

Dr. Ivester is an associate professor of maternal-fetal medicine and an associate professor of maternal and child health at the University of North Carolina at Chapel Hill. Dr. Dotters-Katz is a maternal-fetal medicine fellow at University of North Carolina at Chapel Hill, who completed her ob.gyn. residency at Duke University. Her academic interests include oncology and infectious diseases as they relate to pregnancy. The authors reported having no financial disclosures. Email them at obnews@frontlinemedcom.com.

Pages

Recommended Reading

Study found two-way link between IBD and cervical cancer
MDedge Hematology and Oncology
Vaccine pioneer begins reign as acting director of the National Cancer Institute
MDedge Hematology and Oncology
High rates of oophorectomy documented in premenopausal women
MDedge Hematology and Oncology
Type, location of BRCA mutations influence risk
MDedge Hematology and Oncology
SLN mapping found accurate in endometrial cancer
MDedge Hematology and Oncology
Model accurately spots low-risk endometrial cancer
MDedge Hematology and Oncology
HPV-targeted TILs trigger CR in some advanced cervical cancer patients
MDedge Hematology and Oncology
Biomarker is linked to rucaparib benefit in ovarian cancer
MDedge Hematology and Oncology
Power morcellation debate: Crunching the data
MDedge Hematology and Oncology
QOL independently predicts outcomes in ovarian cancer
MDedge Hematology and Oncology